Phase 2 N=10 Preventing Anaphylaxis With Acalabrutinib
Food Allergy · Food Allergy Peanut
Primary: Highest Dose of Peanut That is Tolerated During Oral Food Challenge — 29; 4,044 mg — p=0.002
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=25 Pilot Study Using Molecular Profiling to Find Potential Targets & Select Treatments for Pts With Met br ca
Metastatic Breast Cancer
Primary: Growth Modulation Index (GMI) Greater Than or Equal to 1.3 — 25 Participants
N/A N=200 A Clinical Study to Evaluate Effects of an Oral Rinse on Plaque and Gingivitis
Plaque
Primary: Plaque Index Score Per Participant at 6 Months — 2.12; 2.70; 2.23; 2.84 score on a scale — p=<0.0001
Phase 2 N=14 Neurobiological Drivers of Mobility Resilience: The Dopaminergic System
Parkinsonian Signs in Older Persons
Primary: Average Gait Speed — 0.973 meters/second — p=0.015
Phase 2 N=24 A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin
Tuberculosis
Primary: Number of Myelomonocytic Cells in the Blood — 3197; 4340; 3390; 3241 cells per microliter (µL)
Phase 3 N=408 Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults
Chikungunya Virus Infection
Primary: Geometric Mean Titer (GMT) of CHIKV-specific Neutralizing Antibodies as Determined by Microneutralization (μPRNT) Assay in Subjects Who Tested Negative for CHIKV…
Phase 2 N=125 Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study
Alzheimer Disease · Cognitive Decline
Primary: Standardized Uptake Value Ratios (SUVrs) Calculated From [18F]AV-1451 PET Scans — 1.09 standardized uptake value ratio
N/A N=29 Non-pharmaceutical Motion Sickness Mitigation
Healthy
Primary: Motion Perception — 55.3; 49.7; 50.1 score on a scale
N/A N=40 Diagnostic Ultrasound for Measuring Fat of the Body
Subcutaneous Fat
Primary: Difference in Thickness of Subcutaneous Fat at Different Anatomic Sites on the Body — .56; .60; .83; 1.65 average fat measurement (cm)
N/A N=23 Acceptance of the CP950 Sound Processor
Hearing Loss, Sensorineural
Primary: Acceptability Ratings for the CP950 Sound Processor Compared to Subjects' Own Processors, Summarized by the Overall Hearing Performance Score. — 3.6 Units on a likert…
Phase 2 N=148 Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis
Atopic Dermatitis
Primary: Percent Change From Baseline to Week 16 in EASI Score — NA; NA; NA; NA Percentage of change from baseline — p=0.888
Phase 2 N=148 Impact of Progesterone on Stress Reactivity and Cannabis Use
Cannabis Use
Primary: Cannabis Craving — 3.7; 3.4; 4.3; 4.5 units on a scale
N/A N=45 Effectiveness of Orthokeratology in Myopia Control
Myopia
Primary: Axial Length — 25.32; 26.08 mm
Phase 2 N=151 Efficacy and Safety of RZL-012 on Submental Fat Reduction
Submental Fat
Primary: Efficacy -Proportion of Subjects With at Least a 1-grade Improvement in the C-CAT Scale at Day 84 — 43; 39; 27 participants
Phase 4 N=26 A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Cystic Fibrosis
Primary: Part 1 Coefficient of Fat Absorption (CFA) — 85.53; 84.59 percentage of fat intake absorbed